The US pharmaceutical company Scorpion Therapeutics has started conducting the first clinical trial of its new EGFR-targeted therapy, 'STX-721,' on patients in South Korea.

The Ministry of Food and Drug Safety (MFDS) has approved ‘The first human clinical trial of STX-721 enrolling patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations.’

The Phase 1/2 clinical trial of STX-721 will be conducted at Seoul National University Hospital.

Scorpion Therapeutics and Pierre Fabre, a French pharmaceutical company, have entered an exclusive collaboration and license agreement to co-develop STX-721 and STX-24